A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer

Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncol Res
Hoofdauteurs: Fujiwara, Atsushi, Yoshida, Masamichi, Fujimoto, Hajime, Nakahara, Hiroki, Ito, Kentaro, Nishihama, Kota, Yasuma, Taro, Hataji, Osamu, Taguchi, Osamu, D’Alessandro-Gabazza, Corina N., Gabazza, Esteban C., Kobayashi, Tetsu
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Cognizant Communication Corporation 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7844677/
https://ncbi.nlm.nih.gov/pubmed/29321093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504018X15151523767752
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items